Literature DB >> 7885475

Multiple defects and perinatal death in mice deficient in follistatin.

M M Matzuk1, N Lu, H Vogel, K Sellheyer, D R Roop, A Bradley.   

Abstract

Follistatin, an activin-binding protein and activin antagonist in vitro, can bind to heparan sulphate proteoglycans and may function in vivo to present activins to their receptors. In the mouse, follistatin messenger RNA is first detected in the deciduum (on embryonic day 5.5), and later in the developing hindbrain, somites, vibrissae, teeth, epidermis and muscle. In Xenopus laevis, overexpression of follistatin leads to induction of neural tissue. Here we use loss-of-function mutant mice to investigate the function of follistatin in mammals. We find that follistatin-deficient mice are retarded in their growth, have decreased mass of the diaphragm and intercostal muscles, shiny taut skin, skeletal defects of the hard palate and the thirteenth pair of ribs, their whisker and tooth development is abnormal, they fail to breathe, and die within hours of birth. These defects are more widespread than those seen in activin-deficient mutant mice, indicating that follistatin may modulate the actions of several members of the transforming growth factor-beta family.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7885475     DOI: 10.1038/374360a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  136 in total

1.  Gene interference using antisense oligodeoxynucleotides on whole chick embryos. Optimal ring and roller-bottle culture technique.

Authors:  J Cooke; A Isaac
Journal:  Mol Biotechnol       Date:  2000-07       Impact factor: 2.695

2.  Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action.

Authors:  Melissa Braga; Shalender Bhasin; Ravi Jasuja; Shehla Pervin; Rajan Singh
Journal:  Mol Cell Endocrinol       Date:  2011-11-25       Impact factor: 4.102

3.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

Review 4.  Current perspectives on the genetic causes of neural tube defects.

Authors:  Patrizia De Marco; Elisa Merello; Samantha Mascelli; Valeria Capra
Journal:  Neurogenetics       Date:  2006-08-29       Impact factor: 2.660

5.  Stimulation of FSHbeta transcription by blockade of endogenous pituitary follistatin production: Efficacy of adenoviral-delivered antisense RNA in the rat.

Authors:  Daniel J Haisenleder; Kevin W Aylor; Laura L Burger; Alan C Dalkin; John C Marshall
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

6.  MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration.

Authors:  Lin Zhang; Maoxian Deng; Ranjani Parthasarathy; Lei Wang; Maureen Mongan; Jeffery D Molkentin; Yi Zheng; Ying Xia
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

7.  FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.

Authors:  Abir Mukherjee; Yisrael Sidis; Amy Mahan; Michael J Raher; Yin Xia; Evan D Rosen; Kenneth D Bloch; Melissa K Thomas; Alan L Schneyer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 8.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

9.  Keratinocyte-derived follistatin regulates epidermal homeostasis and wound repair.

Authors:  Maria Antsiferova; Jennifer E Klatte; Enikö Bodó; Ralf Paus; José L Jorcano; Martin M Matzuk; Sabine Werner; Heidi Kögel
Journal:  Lab Invest       Date:  2008-12-15       Impact factor: 5.662

Review 10.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.